Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT05653804
Active, not recruiting Not applicable

Impact of Tele-visit on Patients Continous Positive Airway Pressure (CPAP) Follow-up by Home Care Provider

NCT05653804 · tracked via the Priya Life Science France tracker
Sponsor
AGIR à Dom
Phase
Not applicable
Started
2023-04-01
Last updated
2026-02-12

Condition(s) studied

Obstructive Sleep Apnea

Investigational drug(s) / intervention(s)

tele-visit

tele-visit: The remote visit content for CPAP follow up is based on home visit framework and carried out from a secure platform for sharing health data.

Study summary

To determine the impact of telecare on continous positive airway pressure (CPAP) patients follow up by home care provider (HCP)

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 18 years * CPAP ≥ 12 months and annual followed by "AGIR à dom" health care provider. * Compliance with CPAP ≥ 4h/night and AHI ≤ 5 events/hour on machine report for the 3 months prior to inclusion Exclusion Criteria: * Follow-up by AGIR à dom. for an other service than package F9.1 : CPAP follow-up and remote monitoring * Unacceptable level of mask leakage * Patient unavailable or willing to move within the next 12 months to an area not covered by AGIR à dom. * Patient considered by the investigator to be unfit for a tele-visit

Primary outcome measure(s)

  • To compare CPAP compliance between the two management modalities — Over the 3 months (tele)visit follow-up
    CPAP mean compliance between intervention and control groups, adjusted for the three months prior to inclusion : in hours/day, collected on the CPAP remote monitoring report

Trial sites (1)

FacilityCityRegionStatus
AGIR à dom. Meylan France

More AGIR à Dom trials in France

Physical Activity Program for Reducing Blood Pressure in Sleep Apnea Patients With Resistant Hypertension Recruiting

Other trials for the same condition

Hypercapnic Burden in Adults With Obesity Undergoing Diagnostic Polysomnography for Suspected Obstructive Sleep Apnea Starting soon
Systematic Screening for Obstructive Sleep Apnea During Preoperative Consultation Using AI-preoperative Agents Active, not recruiting
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy Active, not recruiting
Patients with Coronary Artery Disease or At High Cardiovascular Risk: Measuring Compliance with Treatment for Obstructive Sleep Apnea Syndrome Recruiting
Real-World Performance and Safety of Apneal Dx for Sleep Apnea Screening Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05653804 on ClinicalTrials.gov ↗ ← All trials in France